Erschienen in:
01.03.2023 | Review
Anticholinergic Use for OAB in the Older Woman: An Update
verfasst von:
Berkley Davis, Katherina Chen, Olivia Markert, Jacqueline Zillioux
Erschienen in:
Current Geriatrics Reports
|
Ausgabe 2/2023
Einloggen, um Zugang zu erhalten
Abstract
Purpose
This expert narrative review discusses the role of anticholinergic therapy for overactive bladder in older women with a focus on recent evidence regarding serious safety concerns.
Recent Findings
Anticholinergics are the most commonly utilized treatment for overactive bladder; however, recent large observational studies suggest a significant association between anticholinergic use for overactive bladder and increased risk of dementia. Additional studies have also raised concerns for increased risk of falls, fractures, and all-cause mortality. Differences may exist among various specific anticholinergic drugs, with highest risk associated with oxybutynin. Similar risks have not been found with the other class of overactive bladder pharmacotherapy, beta-3 adrenergic agonists.
Summary
Older women are at increased risk for overactive bladder and are particularly vulnerable to the adverse side effects of anticholinergic medication. Although further research is needed, given mounting concerns for serious and irreversible potential adverse effects associated with anticholinergic use for overactive bladder, this class should be used with caution in older women and alternative effective therapies should be considered.